IIB

Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function

Friday, September 24, 2021 - 1:30pm

Data from the World Health Organization shows that diabetes kills about 3.4 million people worldwide each year.

Key Points: 
  • Data from the World Health Organization shows that diabetes kills about 3.4 million people worldwide each year.
  • Nemaura Medical Inc. (NASDAQ: NMRD ) has spent the last decade developing the worlds first daily-wear, noninvasive glucose sensor and integrated healthcare app.
  • The companys BEAT(R) diabetes platform, inclusive of sugarBEAT(R) CGM and proBEAT(TM), which combines noninvasive glucose data processed using artificial intelligence (AI) and a digital healthcare subscription service, is clearly differentiated from others in form and function.
  • Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Awakn Life SciencesAcquires Exclusive Rights to MDMA Research from Imperial College London

Thursday, September 23, 2021 - 12:30pm

This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the data from the phase IIa Bristol Imperial MDMA in Alcoholism Study (BIMA) from Imperial College London, which has one of the world's leading psychedelics research centers.
  • The results which were published in February 2021, indicated that MDMA has the potential to be more effective at treating AUD.
  • This data will assist Awakn's progress by enabling a better design and more efficient execution of its clinical program.
  • Awakn will now be able to accelerate its clinical research into a phase IIb randomized controlled trial (RCT) in the U.K.

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Thursday, September 23, 2021 - 4:08pm

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Thursday, September 23, 2021 - 4:05pm

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

Nemaura Medical Inc. (NASDAQ: NMRD) Offers Sought-After Solutions in Areas of Unmet Medical Need

Wednesday, September 22, 2021 - 1:30pm

Safe to say, the industry is looking for solutions, particularly more efficient ones that improve health outcomes and lower direct and indirect costs.

Key Points: 
  • Safe to say, the industry is looking for solutions, particularly more efficient ones that improve health outcomes and lower direct and indirect costs.
  • The answer is found in technology, with healthtech (healthcare technology) and medtech (medical technology) buzzwords speaking to leveraging next-generation innovation in a bid to flatten the healthcare spending curve.
  • Some companies, such as Nemaura Medical Inc. (NASDAQ: NMRD), are specializing in certain areas of unmet medical need, such as diabetes and obesity.
  • Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices.

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

Tuesday, September 14, 2021 - 12:00pm

The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs - pharmacologically inactive compounds which are metabolised inside the body to produce an active drug.

Key Points: 
  • The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs - pharmacologically inactive compounds which are metabolised inside the body to produce an active drug.
  • The new substances include novel derivatives of known compounds, increasing the confidence in therapeutic effects and safety profile while offering optimised characteristics.
  • Lars Wilde, Chief Business Officer, President and Co-founder, COMPASS Pathways, said: We are delighted to be working with Matthias and MiHKAL GmbH.
  • This agreement will strengthen and expand our IP and development portfolio with new compounds.

Northstar Engages Boart Longyear for Miller Gold Drill Program and Closes Private Placement

Monday, September 13, 2021 - 9:00pm

Northstar Gold Corp. also announces the Company has closed its second and final tranche of its previously announced $2.5 million non-brokered private placement of units ("Units") for gross proceeds of CDN$104,000.

Key Points: 
  • Northstar Gold Corp. also announces the Company has closed its second and final tranche of its previously announced $2.5 million non-brokered private placement of units ("Units") for gross proceeds of CDN$104,000.
  • Northstar drilled 5,023 metres in 28 holes at Miller in 2020, targeting near-surface high-grade and bulk-tonnage gold-telluride mineralization at Miller.
  • Northstar also commissioned a $350,000 property-wide 3D IP, gravity and magnetic geophysics program on the Miller Gold Property in 2020 to further define gold mineralization controls at depth.
  • Northstar recently completed a 1,990 metre Phase IIA follow up diamond drill program at Miller on April 27th, 2021.

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Friday, September 10, 2021 - 12:00pm

Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need.

Key Points: 
  • Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need.
  • Mr Morris said: For over a decade, Jason and I have worked together studying the chemistry and pharmacology of psychedelics.
  • Lars Wilde, Chief Business Officer, President and Co-founder, COMPASS Pathways, said, I am delighted to welcome Hamilton to our team.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

IBJ Media Acquires Grow INdiana Media Ventures LLC, Parent Company of Inside INdiana Business

Tuesday, August 31, 2021 - 3:30pm

IBJ Media, the owner and publisher of the Indianapolis Business Journal and The Indiana Lawyer, today announces its acquisition of Grow INdiana Media Ventures LLC , the parent company of the Inside INdiana Business brand of business news products.

Key Points: 
  • IBJ Media, the owner and publisher of the Indianapolis Business Journal and The Indiana Lawyer, today announces its acquisition of Grow INdiana Media Ventures LLC , the parent company of the Inside INdiana Business brand of business news products.
  • The five-time Emmy-winning Inside INdiana Business with Gerry Dick television show will become a new division of IBJ Media and will continue to air across all current stations, as will Inside INdiana Business Radio, which broadcasts on 22 stations statewide.
  • Both the IBJ and IIB websites will continue to post news and send e-newsletters daily, with IBJ focused on the central Indiana economy and Inside INdiana Business concentrated on statewide business news.
  • Grow INdiana Media Ventures, the parent company of the powerful Inside INdiana Business brand of multi-media business news products, was created in 2000 by broadcast news veteran Gerry Dick and technology entrepreneur Scott Jones, with Dick eventually taking on full ownership.

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting

Friday, August 27, 2021 - 9:45am

The QUORUM study demonstrates the efficacy and good safety profile of firibastat.

Key Points: 
  • The QUORUM study demonstrates the efficacy and good safety profile of firibastat.
  • In severe patients with an ejection fraction less than 50%, firibastat appears to be more effective than ramipril.
  • For this reason, QUORUMs phase IIb results pave the way for a phase III clinical study in severe patients whose protocol will be finalized with a selected partner pharmaceutical company.
  • Highlights from the phase IIb QUORUM study are included below:
    295 patients were enrolled in the study within 24 hours of a first myocardial infarction.